Policosanol is a natural mixture of long-chain primary aliphatic alcohols, primarily isolated from sugarcane wax (Saccharum officinarum L.). It is a well-established lipid-lowering agent in several countries, including India, where it is marketed as a nutraceutical or dietary supplement. Its primary clinical effect is the reduction of serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol, with a potential increase in high-density lipoprotein cholesterol (HDL-C). The mechanism is distinct from statins, involving the inhibition of hepatic cholesterol synthesis at a different enzymatic step (HMG-CoA reductase activation) and an increase in LDL receptor-mediated catabolism.
Adult: 5mg to 20mg once daily, typically initiated at 10mg once daily with the evening meal. The 10mg strength is the most commonly used maintenance dose.
Note: Administer once daily, preferably with the evening meal to coincide with the peak period of endogenous cholesterol synthesis. Tablet should be swallowed whole with a glass of water.
Policosanol's exact mechanism is not fully elucidated but is distinct from statins. It does not directly inhibit HMG-CoA reductase. Proposed mechanisms include: 1) Regulation of HMG-CoA reductase activity through its phosphorylation/dephosphorylation cycle, reducing the active form of the enzyme. 2) Upregulation of hepatic LDL (Apo B/E) receptors, increasing the clearance of LDL particles from circulation. 3) Inhibition of cholesterol biosynthesis at a step between acetate and mevalonate, possibly at the level of enzymatic conversion of acetyl-CoA to acetoacetyl-CoA. 4) Mild antiplatelet aggregation effects via modulation of thromboxane B2 and serum prostacyclin levels.
Pregnancy: Category N (Not classified by US FDA). Insufficient data on use in pregnant women. Animal studies are inadequate. Contraindicated due to potential risk. Cholesterol is crucial for fetal development.
Driving: Policosanol may cause dizziness in some patients. Caution is advised when driving or operating machinery until the patient's response is known.
| Warfarin, Acenocoumarol | Potential pharmacodynamic synergy increasing INR and bleeding risk. Monitor INR closely. | Major |
| Aspirin, Clopidogrel, NSAIDs | Increased risk of bleeding due to additive antiplatelet effects. | Moderate |
| Statins (Atorvastatin, Rosuvastatin) | Theoretical additive lipid-lowering effect. Combined use is not standard in India; monitor for increased side effects. | Moderate |
| Cyclosporine | Potential unknown interaction due to metabolism pathways. Use with caution. | Moderate |
Same composition (Policosanol (10mg)), different brands: